ArticleJournal of applied genetics2026
Local estrogen therapy effects on DNA methylation dynamics in menopausal women-a cross-sectional preliminary study.
Article in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopause is characterized by a permanent decline in estrogen levels, effecting various tissues and contributing to systemic aging. Reduced hormonal levels negatively impact vaginal health, leading to tissue atrophy, which can be alleviated with topical estrogen therapies. This study aimed to assess the effects of menopausal hormone deficiencies on DNA methylation in vaginal tissue and swabs, compared to buccal swabs, and evaluate the impact of local estrogen therapy on these changes. Samples from 126 women were categorized into three groups: premenopausal, postmenopausal without local estrogen therapy, and postmenopausal with local estrogen therapy. Postmenopausal women with urogenital atrophy exhibited elevated cytosine methylation (5-mC) compared to premenopausal women, whereas those receiving local estrogen therapy had 5-mC levels similar to premenopausal women. Additionally, 5-hydroxymethylcytosine (5-hmC) levels, a marker of demethylation, was also higher in the estrogen-treated group. The 5-mC/5-hmC ratio was notably elevated in women with urogenital atrophy. Significant differences in DNA methylation dynamics were observed in vaginal samples but not in buccal swabs among postmenopausal groups. Menopausal hormonal deficiencies lead to epigenetic changes in vaginal tissue, particularly increased cytosine methylation. Local estrogen therapy can mitigate these changes, providing insights into aging processes. Analyzing DNA methylation in vaginal swabs may serve as a non-invasive tool for monitoring age-related changes and assessing therapeutic efficacy. Further research is needed to understand these epigenetic modifications and their clinical implications.
Indexed as
Identifiers
42036589What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.